100 related articles for article (PubMed ID: 30628449)
1. Total Synthesis of Covalent Cysteine Protease Inhibitor N-Desmethyl Thalassospiramide C and Crystallographic Evidence for Its Mode of Action.
Fournier J; Chen K; Mailyan AK; Jackson JJ; Buckman BO; Emayan K; Yuan S; Rajagopalan R; Misialek S; Adler M; Blaesse M; Griessner A; Zakarian A
Org Lett; 2019 Jan; 21(2):508-512. PubMed ID: 30628449
[TBL] [Abstract][Full Text] [Related]
2. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
[TBL] [Abstract][Full Text] [Related]
3. Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors.
Silva TL; Dos Santos DA; de Jesus HCR; Brömme D; Fernandes JB; Paixão MW; Corrêa AG; Vieira PC
Bioorg Med Chem; 2020 Aug; 28(15):115597. PubMed ID: 32631567
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the synthesis, design and selection of cysteine protease inhibitors.
Hernandez AA; Roush WR
Curr Opin Chem Biol; 2002 Aug; 6(4):459-65. PubMed ID: 12133721
[TBL] [Abstract][Full Text] [Related]
5. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of the Novel Covalent Cysteine Proteases Inhibitor with Iodoacetic Functional Group.
Hartman K; Mielczarek P; Silberring J
Molecules; 2020 Feb; 25(4):. PubMed ID: 32069913
[TBL] [Abstract][Full Text] [Related]
7. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K.
Altmann E; Cowan-Jacob SW; Missbach M
J Med Chem; 2004 Nov; 47(24):5833-6. PubMed ID: 15537340
[TBL] [Abstract][Full Text] [Related]
8. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
9. 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity.
Setti EL; Davis D; Janc JW; Jeffery DA; Cheung H; Yu W
Bioorg Med Chem Lett; 2005 Mar; 15(5):1529-34. PubMed ID: 15713422
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and matched molecular pair analysis of covalent reversible inhibitors of the cysteine protease CPB.
Matos TKB; Batista PHJ; Dos Reis Rocho F; de Vita D; Pearce N; Kellam B; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2020 Sep; 30(18):127439. PubMed ID: 32717373
[TBL] [Abstract][Full Text] [Related]
12. An Activity-Based Probe for Cathepsin K Imaging with Excellent Potency and Selectivity.
Lemke C; Benýšek J; Brajtenbach D; Breuer C; Jílková A; Horn M; Buša M; Ulrychová L; Illies A; Kubatzky KF; Bartz U; Mareš M; Gütschow M
J Med Chem; 2021 Sep; 64(18):13793-13806. PubMed ID: 34473502
[TBL] [Abstract][Full Text] [Related]
13. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
14. Arylaminoethyl amides as novel non-covalent cathepsin K inhibitors.
Altmann E; Renaud J; Green J; Farley D; Cutting B; Jahnke W
J Med Chem; 2002 Jun; 45(12):2352-4. PubMed ID: 12036343
[TBL] [Abstract][Full Text] [Related]
15. Naphthoquinones as Covalent Reversible Inhibitors of Cysteine Proteases-Studies on Inhibition Mechanism and Kinetics.
Klein P; Barthels F; Johe P; Wagner A; Tenzer S; Distler U; Le TA; Schmid P; Engel V; Engels B; Hellmich UA; Opatz T; Schirmeister T
Molecules; 2020 Apr; 25(9):. PubMed ID: 32354191
[TBL] [Abstract][Full Text] [Related]
16. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.
Oballa RM; Truchon JF; Bayly CI; Chauret N; Day S; Crane S; Berthelette C
Bioorg Med Chem Lett; 2007 Feb; 17(4):998-1002. PubMed ID: 17157022
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP
J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817
[TBL] [Abstract][Full Text] [Related]
18. Straightforward synthesis of 2,4,6-trisubstituted 1,3,5-triazine compounds targeting cysteine cathepsins K and S.
Plebanek E; Chevrier F; Roy V; Garenne T; Lecaille F; Warszycki D; Bojarski AJ; Lalmanach G; Agrofoglio LA
Eur J Med Chem; 2016 Oct; 121():12-20. PubMed ID: 27214508
[TBL] [Abstract][Full Text] [Related]
19. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
[TBL] [Abstract][Full Text] [Related]
20. The Alkyne Moiety as a Latent Electrophile in Irreversible Covalent Small Molecule Inhibitors of Cathepsin K.
Mons E; Jansen IDC; Loboda J; van Doodewaerd BR; Hermans J; Verdoes M; van Boeckel CAA; van Veelen PA; Turk B; Turk D; Ovaa H
J Am Chem Soc; 2019 Feb; 141(8):3507-3514. PubMed ID: 30689386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
